The p53 tumor suppressor protein plays a crucial role in regulating cell growth following exposure to various stress stimuli. p53 induces either growth arrest, which prevents the replication of damaged DNA, or programmed cell death (apoptosis), which is important for eliminating defective cells. Whether the cell enters growth arrest or undergoes apoptosis, depends on the ®nal integration of incoming signals with antagonistic eects on cell growth. Many factors aect the cellular response to activated p53. These include the cell type, the oncogenic status of the cell with emphasis on the Rb/E2F balance, the extracellular growth and survival stimuli, the intensity of the stress signals, the level of p53 expression and the interaction of p53 with speci®c proteins. p53 is regulated both at the levels of protein stability and biochemical activities. This complex regulation is mediated by a range of viral and cellular proteins. This review discusses this intriguing complexity which aects the cell response to p53 activation.
Introduction
p53 plays a pivotal role in regulating cell growth and death. Mutations in p53 or inactivation through interaction with viral or cellular proteins are the most frequent alterations observed in cancer cells (Levine, 1997) . The p53 protein has been denoted`the guardian of the genome' for its role in preventing the accumulation of genetic alterations. This task is achieved through the induction of growth arrest or senescence to prevent the replication of damaged DNA. However, the suppression of tumor development is largely dependent on the ability of p53 to eliminate aberrant cells by apoptosis. This link between the apoptotic function of p53 and tumor suppression has been demonstrated both in vitro and in vivo (reviewed in Attardi and Jacks, 1999; Levine, 1997; Vogt Sionov and Haupt, 1998) . While the pathways responsible for p53-mediated growth arrest have essentially been de®ned, the mechanisms underlying the apoptotic activity are only beginning to be described. In this review we will survey factors regulating growth suppression by p53 and how they aect the cellular response to p53: whether to enter growth arrest or to undergo apoptosis.
p53 activities
The p53 tumor suppressor protein is involved in diverse cellular processes, including the regulation of the cell cycle, apoptosis, senescence, DNA repair, cell dierentiation and angiogenesis. These activities are mediated through a variety of biochemical functions, such as transcriptional activation, transrepression, DNA annealing and a 3'?5' exonuclease activity, and they involve a large set of target genes and interacting proteins (reviewed in, Amundson et al., 1998; Bates and Vousden, 1999; Giaccia and Kastan, 1998; Janus et al., 1999; Jayaraman and Prives, 1999; Levine, 1997) . Here we shall focus primarily on the role of p53 in the regulation of cell growth arrest and apoptosis.
Growth arrest p53 plays a role in regulating vital checkpoints during the G1 and G2 phases of the cell cycle ( Figure 1 ). The induction of p21 WAF1/Cip1 is responsible for G1 arrest (reviewed in El- , while the induction of 14-3-3s, and to some extent that of GADD45 gene, mediate the G2 arrest (Hermeking et al., 1997) . These checkpoints prevent cells with damaged genomes from undergoing DNA replication or mitosis. p21 mediates p53-dependent G1 arrest by inhibiting the activity of cyclin-dependent kinases (CDKs), which phosphorylate the retinoblastoma (pRb) gene product. In its hypophosphorylated form, pRb sequesters the E2F transcription factor, thereby preventing transition from G1 to S phase (HengstschlaÈ ger et al., 1999) . The pRb-E2F complex binds the E2F responsive elements and represses the expression of E2F-target genes required for the transition into S phase. In addition, pRb recruits histone deacetylase (HDAC1) which blocks transcription by promoting nucleosome compaction (Brehm et al., 1998) . p21 also promotes growth arrest by preventing PCNA from activating DNA polymerase d essential for DNA replication (Waga et al., 1994) . These ®ndings are consistent with the impairment of G1 arrest in p21-de®cient ®broblasts (Deng et al., 1995) . p53 can also trigger growth arrest in a p21-independent manner. By binding to Cyclin H and p36 Mat1 , p53 inhibits the protein kinase complex CDK7/ CyclinH1/Mat1 (a CDK-activating kinase termed CAK kinase) which activates the CDK2/Cyclin A kinase required for the G1/S transition .
In addition to G1 arrest, p53 has been shown to induce an ecient G2 arrest. At least two p53 target genes can mediate this activity. The product of the 14-3-3s gene sequesters the phosphorylated form of cdc25C, a phosphatase of the cyclinB/cdc2 complex that is essential for the G2/M transition (Peng et al., 1997 ). An additional mechanism by which p53 inhibits the cyclinB/cdc2 complex is through the induction of GADD45 which disrupts this complex, probably via a direct interaction with cdc2 . Although G2 arrest can occur in the absence of p21 or p53, both of these proteins are essential for sustaining the G2 arrest after DNA damage (Bunz et al., 1998) . Moreover, p53 is involved in a mitotic spindle checkpoint and is required to prevent endoreduplication of 4N cells. The presence of p21 appears necessary to prevent improper reentry into S phase that would lead to polyploidy (Stewart et al., 1999) .
Apoptosis
The apoptotic mechanisms of p53 have been intensively dissected and multiple pathways have been identi®ed. This eort revealed the involvement of multiple apoptotic pathways. While p53-mediated growth arrest is dependent on its sequence-speci®c transactivation (SST) function, p53-promoted apoptosis is mediated by both SST-dependent and -independent pathways which cooperate for full apoptotic response (Figure 2) (Amundson et al., 1998; Bates and Vousden, 1999; Vogt Sionov and Haupt, 1998) . To what extent each pathway contributes to the apoptotic activity of p53 remains a matter of controversy. In the following sections we will discuss the contribution of new ®ndings to the emerging picture of how p53 may mediate apoptosis.
SST-dependent apoptosis by p53
Transcriptional activation by p53 can contribute to its apoptotic activity (Choisy Rossi et al., 1998; Yonish-Rouach et al., 1996) , and in some cases is essential (Attardi et al., 1996; Sabbatini et al., 1995b) . Several p53-induced target genes can promote apoptosis (Figure 2 ), although the expression of each alone is usually insucient to cause signi®cant cell death. Hence, the apoptotic target genes may need to act in concert, by activating parallel apoptotic pathways, in order to mount a full apoptotic response. The apoptotic target genes of p53 may be divided into two major families. The ®rst one encodes proteins acting at the level of receptor signaling for apoptosis, while the second family includes proteins acting downstream by activating apoptotic eector proteins.
By inducing proteins acting at the receptor signaling level, p53 may sensitize cells to apoptosis. For instance, the insulin-like growth factor-1-binding protein 3 (IGF-BP3) induces apoptosis by blocking the survival signaling by IGF-1 (Buckbinder et al., 1995) . The combined repression of IGF-1 receptor (IGF-IR) by p53 assures an ecient block of this survival pathway (Prisco et al., 1997) . p53 also activates an important death receptor, Fas/Apo-1/CD95, which plays an important role in the regulation and function of the immune response. Fas/Apo-1 is induced by p53 in response to DNA damage, and p53 responsive elements have been identi®ed in the Fas gene (OwenSchaub et al., 1995) . In addition, p53 may facilitate the transport of Fas from the Golgi to the membrane . Fas is essential for T-cell killing in response to anti-cancer drugs (Friesen et al., 1996) and for Myc-mediated apoptosis (Hueber et al., 1997) . Both responses are p53-dependent, hence linking Fas with the apoptotic pathway of p53. Indeed, hepatoma cells expressing wild-type (wt) p53, but not mutant p53, are more sensitive to drug-induced apoptosis mediated by the Fas pathway (MuÈ ller et al., 1997) . Further, p53-induced apoptosis is impaired in lpr (Fas-de®cient mice) and gld (Fas ligand-de®cient mice) derived embryonic ®broblasts . p53 also induces another death receptor, KILLER/DR5 . To date there is no direct evidence for the Figure 1 Induction of growth arrest by p53. Activation of p53 induces the transcription of target genes involved in cell cycle regulation. p21 is central for the induction of G1 arrest/ senescence and replication arrest. GADD45 and 14-3-3s promote G2 arrest through separate pathways. The parallel contribution of ATM is also included. ?indicates induction, whereas \ inhibition Figure 2 p53-mediated apoptosis through SST-dependent (solid arrows) and SST-independent (broken lines) mechanisms. Apoptotic target gene products induced by p53 include those operating at the membrane signaling level (e.g., IGF-BP3, Fas/ Apo-1, KILLER/DR5) and those signaling to the mitochondria by elevating ROS (e.g., PIG3) or by releasing cytochrome C and AIF (e.g., Bax). The SST-independent apoptotic pathways include repression of both survival promoting genes (e.g., IGF-1R; presenilin) and inhibitors of apoptosis (e.g., Bcl-2), as well as activation of caspase and enhancing the transport of Fas from the Golgi to the cell membrane. ? indicates induction, whereas \ inhibition role of these receptors in p53-mediated apoptosis, and in some cases Fas is not essential for this function of p53 (Reinke and Lozano, 1997b) . However, upregulation of these receptors may contribute to p53-mediated apoptosis by sensitizing these cells for death signals induced by their respective ligands.
Earlier stages in the induction of apoptosis are associated with mitochondrial changes (reviewed in Dragovich et al., 1998) . One p53 target gene linking p53 to such mitochondrial events is bax. The Bax protein promotes apoptosis by facilitating the release of apoptosis-inducing factor (AIF) and cytochrome C from the mitochondria, which in turn triggers a cascade of caspase activation (Narita et al., 1998; Susin et al., 1999) . The apoptotic activity of Bax is important for tumor suppression (Yin et al., 1997) , what explains the selection for bax mutations in colon tumors (Rampino et al., 1997) . Bax seems to be essential for p53-mediated cell death in brain tumors (Yin et al., 1997) and ®broblasts (McCurrach et al., 1997) but not in thymocytes (Brady et al., 1996) . Moreover, Bax expression can enhance the chemosensitivity of breast cancer cell lines (Wagener et al., 1996) . Thus, Bax appears to contribute only in part to p53-mediated cell death.
An additional route by which p53 may signal to the mitochondria is through the elevation of the levels of reactive oxygen radicals (ROS) (Figure 2 ) (Johnson et al., 1996) . Polyak et al. (1997) isolated several p53-induced genes (PIGs) with a potential to induce an oxidative stress. In particular, PIG3 shares homology with an NADPH-quinone oxidoreductase, which generates ROS . When overexpressed alone, PIG3 failed to initiate apoptosis, implying that other signals must be activated in parallel . p53 also induces the expression of other genes implicated in the induction of apoptosis such as PAG608 (Israeli et al., 1997) , however, their contribution to p53-dependent apoptosis is not clear yet. It must be kept in mind that only a speci®c subset of p53 target genes may mediate apoptosis while other target genes may have no eect or even an antagonistic eect (e.g., p21 see below).
Overall, there is ample evidence to support a role for SST in the apoptotic function of p53. This is consistent with kinetics studies showing that wt p53 induces apoptosis faster and more eciently than a SSTde®cient p53 mutant (Haupt et al., 1995b) . However, whether SST is obligatory for the induction of apoptosis remains controversial (for reviews see Bates and Vousden, 1999; Vogt Sionov and Haupt, 1998) . The extent by which the SST pathway contributes to the overall apoptotic response of p53 can be in¯uenced by many variables, including cell type and cellular context . Nevertheless, it appears that only a fraction of the important p53 target apoptotic genes have been identi®ed. It is likely that future screens will reveal additional target genes that mediate apoptosis as well as genes that inhibit survival pathways.
SST-independent apoptosis by p53 The initial indication for a SST-independent apoptotic activity of p53 was based on the observation that p53 can induce apoptosis in the presence of RNA and protein synthesis inhibitors (Caelles et al., 1994) . This function of p53 was directly demonstrated by using SSTde®cient mutants of p53 that induce apoptosis in HeLa cervical carcinoma, Saos-2 osteosarcoma, A431 keratinocytic tumor cell line, and M1 myeloblastic leukemia cells (Bates and Vousden, 1999; Bissonnette et al., 1997; Chen et al., 1996; Guillouf et al., 1998; Haupt et al., 1995b) . The mechanisms underlying the SST-independent apoptotic activity of p53 are poorly understood, although recent research may provide some clues. A molecular event shared by some of the experimental systems shown to be sensitive to SSTindependent apoptosis by p53 is the loss of the pRb/ pRb family function. A major consequence of this loss is the release of E2F family members. Deregulation of E2F-1, but not other E2F proteins, induces apoptosis in many cell types (reviewed in Dyson, 1998) . Although E2F-1 can induce apoptosis in a p53-independent manner (reviewed in Dyson, 1998) , there is strong evidence linking E2F-1 and p53 in the induction of apoptosis. E2F-1 synergizes with p53 in the induction of apoptosis (Wu and Levine, 1994) , and in some cases p53 can contribute to this activity of E2F-1 (Dyson, 1998) . E2F-1-induced apoptosis of epidermal keratinocytes is reduced in mice de®cient for p53, whereas the proliferative activity of E2F-1 is unaected (Pierce et al., 1998) . Similarly, the apoptotic activity of p53 depends on E2F-1. Transgenic mice heterozygote for the expression of mutant Large T antigen, which neutralizes pRb but not p53 function, develop brain tumors and exhibit high levels of apoptosis (Symonds et al., 1991) . Elimination of E2F-1 from these mice reduces the levels of apoptosis by 80%, a reduction similar to that obtained by eliminating p53 (Pan et al., 1998) . These ®ndings are consistent with the relative resistance of E2F-1-derived ®broblasts to DNA damage (Meng et al., 1999) . The extent by which E2F-1 contributes to the SST-independent apoptotic activity of p53 remains open and deserves further evaluation. If the SST-independent apoptotic activity of p53 is mediated primarily through E2F-1, it is expected that E2F-1 would synergize with p53 apoptotic target genes and with SST-de®cient mutants of p53 to induce apoptosis.
An insight into the SST-independent apoptotic activity of p53 was gained from studies de®ning functional domains responsible for growth suppression. Walker and revealed a proline rich region (60 ± 90), containing 5 PXXP partially conserved motifs, which is important for growth suppression by p53. Deletion of these motifs does not aect SST or the induction of growth arrest (Venot et al., 1998) , but impairs the ability of p53 to suppress colony growth (Walker and and to induce apoptosis triggered by E1A (Sakamuro et al., 1997) . Intriguingly, deletion of the proline rich region abolishes the ability of p53 to induce PIG3 expression, but not other target genes such as p21, mdm2 and bax, being consistent with the requirement for this region for ROS production by p53 (Venot et al., 1998) . This prolinerich region was also shown to be required for p53-dependent growth arrest through Gas-1 (Ruaro et al., 1997) , a plasma membrane protein highly expressed during G 0 . These ®ndings are further supported by the identi®cation of a germ line mutation within this region (proline 82) in cancer patients with Li-Fraumeni syndrome (Sun et al., 1996) . However, a direct role for this region in mediating the SST-independent apoptotic pathway of p53 is yet to be demonstrated. The role of the proline rich region may be more involved than originally thought, as it may act as a negative regulatory domain. Synthetic peptides spanning this domain were able to activate p53 for sequence speci®c DNA binding in vitro (MuÈ ller-Tiemann et al., 1998) . It is plausible that the proline rich region may contribute to SST-independent apoptosis through multiple mechanisms: the induction of ROS on the one hand and inhibition of SST-mediated growth arrest on the other. These activities may be mediated through interaction with SH3 containing proteins.
Several studies suggest a role for p53 transrepression in the induction of apoptosis. Expression of Bcl-2, E1B 19 kD and WT1 attenuates p53-mediated apoptosis with the concurrent relief of transrepression without compromising SST or the induction of growth arrest (Murphy et al., 1996; Sabbatini et al., 1995a; Vogt Sionov and Haupt, 1998) . Similar correlation has been recently observed in the collaboration between p53 and pRb in the induction of apoptosis (Hsieh et al., 1999) . Among the many genes that can be repressed by p53, bcl-2, IGF-1R, microtubule-associated protein-4 (MAP4), inosine-5'-monophosphate dehydrogenase (IMPD) and presenilin-1 are the most relevant since they can attenuate the apoptotic activity of p53 (Liu et al., 1998; Roperch et al., 1998; Vogt Sionov and Haupt, 1998) . Moreover, p53 represses ribosomal gene transcription (Budde and Grummt, 1999) and inhibits RNA polymerase III-directed transcription (Cairns and White, 1998) . Suppression of genes essential for cell survival is a likely route to promote apoptosis. Taken together, a correlation exists between transrepression and the induction of apoptosis by p53. The requirement for the suppression of these genes in the apoptotic activity of p53 demands direct demonstration.
Another likely mechanism for p53 SST-independent apoptotic activity is through direct interaction with apoptosis inducing proteins. Examples are the helicases XPB and XPD, which are required for p53-mediated apoptosis without impairing growth arrest by p53 (Wang et al., 1996) , or proteins that interact with antiapoptotic proteins, such as p53BP2 (Naumovski and Cleary, 1996) . Recently, p53 was shown to cause caspase activation in cell-free extracts from IRtransformed, but not normal, ®broblasts by a mechanism independent of transcription or presence of Bax or cytochrome C . This activation of caspase by p53 was oncogene dependent, a ®nding consistent with the requirement of caspase-9 and Apaf-1 in p53-dependent Myc-induced apoptosis (Soengas et al., 1999) . The caspase activation was not an immediate event, but delayed, suggesting that a prolonged exposure to p53 elicits this response. This kinetics may be crucial for the cellular response to p53, determining whether the cell will be committed to death.
Regulation of p53
The p53 protein is activated by several stress conditions including DNA damage, hypoxia, changes in the redox potential, a reduction in the ribonucleoside triphosphate pool, adhesion and the expression of several oncogenes (reviewed by Amundson et al., 1998; Giaccia and Kastan, 1998) . In response to these signals, p53 is subjected to extensive post-translational modi®cations, including phosphorylation and acetylation, which modulate its stability and activities (Jayaraman and Prives, 1999; Meek, 1998; Sakaguchi et al., 1998) . The p53 protein is regulated at two main levels: at the level of p53 protein stability, and at the level of biochemical activity whereby p53 is converted from a latent into an active protein (Table 1) . Compilation of studies over the past two years supports the notion that stabilization of p53 plays a major role in p53 activation, whereas modi®cations unrelated to p53 stabilization may regulate the speci®c activity of p53. Both the expression and activity of p53 are tightly regulated by multiple positive and negative feedback loops. In this section we outline the mechanisms by which various stress conditions are conveyed into signals that regulate p53 stability and activity, with a focus on the role of Mdm2 in this regulation.
Regulation of p53 stability
The p53 protein has a very short half-life (Blagosklonny, 1997). Exposure of cells to DNA damage, such as that caused by ionizing radiation (IR), ultraviolet light (UV) or anti-cancer drugs, leads to a rapid accumulation of the p53 protein (reviewed in Giaccia and Kastan, 1998) . A key player in this regulation is the Murine Double Minute-2 (Mdm2) proto-oncoprotein. Mdm2 binds p53 within its transactivation domain, blocks its transcriptional activity, and abrogates the ability of p53 to induce growth arrest and apoptosis. Since mdm2 is a direct target of p53, a negative autoregulatory feedback loop exists between these two proteins (reviewed in Freedman and Kubbutat and Vousden, 1998; Lozano and Montes de Oca Luna, 1998) . The importance of this tight regulation has been demonstrated by the lethality of mdm-2 7/7 embryos, which are rescued by knocking out p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995) . A major mechanism by which Mdm2 regulates p53 is by promoting it for degradation by the ubiquitin-proteasome system Kubbutat et al., 1997) . Mdm2 promotes p53 degradation by facilitating the nuclear-cytoplasmic export of p53 (Freedman and Roth et al., 1998) , and by promoting p53 ubiquitination in vitro and in vivo (Fuchs et al., 1998a) . Consequently, Mdm2 is thought to be the E3 ligase in this process (Honda et al., 1997) .
Not only Mdm2, but also the human papillomavirus (HPV) E6 protein promotes p53 degradation via the ubiquitin-proteasome system. The latter involves the E6-associated protein (E6-AP) as the E3-ligase (Schener, 1998) . Interestingly, here too nuclear export is required for p53 degradation (Freedman and , suggesting some similarities in the mechanisms by which E6 and Mdm2 promote p53 degradation.
For p53 to persist in an active form, the inhibitory eect of Mdm2 has to be neutralized. Multiple mechanisms have been described through which the inhibitory eect of Mdm2 can be modulated. These include down-regulation of mdm2 expression, prevention of the Mdm2-p53 interaction, and inhibition of Mdm2-mediated degradation of p53. These modes of regulation are described in the following sections.
Delay or inhibition of mdm2 expression A lag exists between the activation of p53 and the consequent induction of mdm2, thus de®ning a time window within which p53 exerts its eects. In some cases, p53 continues to operate even after mdm2 has been induced. For instance, the levels of mdm2 mRNA and protein fall immediately after exposure to UV radiation in a p53-independent manner, and only later increase in a p53-dependent manner (Wu and Levine, 1997) . This allows the rapid accumulation of p53. At high doses of UV the induction of mdm2 is delayed (8 ± 12 h after irradiation) beyond that of p21 (2 ± 5 h after irradiation) (Wu and Levine, 1997) . Such a dierential expression of p53-target genes is confirmed by immunohistochemical analysis of UV-irradiated human skin (O'Grady et al., 1998) . A more dramatic eect was observed after treatment with the topoisomerase inhibitor, etoposide. After treatment with etoposide, mdm2 induction was inhibited, whereas p21 and GADD45 expression increased in a dose-dependent manner (Arriola et al., 1999) , hence ensuring a rapid p53 response. Similarly, the adenoviral E1A protein inhibits the ability of p53 to induce mdm2, but not p21 and bax, by blocking the transacetylase activity of the essential co-factor, p300 (Thomas and White, 1998) . Expression of E1B 19K or Bcl-2 in E1A-transformed cells abrogates p53-dependent apoptosis by restoring mdm2 expression (Thomas and .
On the other hand, p53 activities may be antagonized by factors inducing mdm2 expression, such as the insulin-like growth factor-1 (IGF-1) (Leri et al., 1999) , ®broblast growth factor (bFGF) (Shaulian et al., 1997) and thyroid hormone (T3) receptors (Qi et al., 1999) . A regulatory feedback loop may be depicted between IGF-1 and p53. p53 induces the expression of IGF-BP3 which binds to and inactivates IGF-1, thereby blocking its induction of mdm2. Thus, p53 stability and activity can be modulated through the regulation of mdm2 synthesis.
Prevention of the p53-Mdm2 interaction It has been demonstrated that interference with the Mdm2-p53 interaction is sucient for the accumulation of active p53. This was based on studies using p53 or Mdm2 bearing mutations in the respective binding sites Kubbutat et al., 1997) , antibodies or mini-proteins directed to the binding site (Blaydes . This can occur if the Mdm2 eect is neutralized after DNA damage. Indeed, a reduction in Mdm2-p53 complex formation was observed under these conditions (Fuchs et al., 1998a) . Recent studies provide mechanistic explanations for how this regulation may occur. In response to DNA damage, p53 is phosphorylated on serine 15 by DNA-dependent protein kinase (DNA-PK) , ATM (mutated in Ataxia Telangiectasia, A-T) (Banin et al., 1998; Canman et al., 1998; Khanna et al., 1998) and ATR (Tibbetts et al., 1999) . This phosphorylation impairs the interaction between p53 and Mdm2, and may account for the stabilization of p53 after activation by these kinases . The eect of DNA-PK is enhanced by phosphorylation of Mdm2, which blocks the ability of Mdm2 to associate with p53 (Mayo et al., 1997) . Another important regulatory site within the Mdm2 binding region of p53 is serine 20. This site is phosphorylated in response to irradiation . Substitution of serine 20 by the neutral alanine (p53Ala20) signi®cantly increases the susceptibility of p53 to the negative regulation by Mdm2 as well as enhances the p53-Mdm2 complex formation (Unger et al., 1999) .
Another regulator of p53 stability is the Jun-NH 2 -terminal kinase-1 (JNK1). Under stress conditions, JNK1 stabilizes p53 presumably by reducing the interaction of p53 with Mdm2 and with JNK1 in a phosphorylation-dependent manner (Fuchs et al., 1998c) . However, in non-stressed cells this MAP kinase targets p53 ubiquitination and degradation (Fuchs et al., 1998b) . The regulation of p53 by Mdm2 and JNK1 may be cell cycle dependent, as JNK1-p53 complexes and Mdm2-p53 complexes were preferentially formed in G 0 /G 1 and S/G2M phases of the cell cycle, respectively (Fuchs et al., 1998b) .
Inhibition of Mdm2-mediated p53 degradation Another mechanism by which p53 can be stabilized, is by blocking the ability of Mdm2 to promote p53 degradation. The c-Abl non-receptor tyrosine kinase has been shown to cooperate with p53 in growth suppression (reviewed in Kharbanda et al., 1998) . Both are activated by similar genotoxic stress stimuli, and a physical and functional interaction between these proteins has been described (Kharbanda et al., 1998) . Recently we provided an explanation for the cooperative eect of c-Abl on p53 transcriptional activity. cAbl stabilizes the p53 protein by neutralizing the eect of Mdm2 on p53 degradation . Further, c-Abl does not alter the amount of Mdm2 bound to p53, but rather keeps p53 functionally active in the presence of Mdm2. Both the transcriptional activity of p53 and its apoptotic function proceed normally in the presence of Mdm2 . Thus, c-Abl may extend the time window of p53 activation by neutralizing the negative eects of Mdm2.
Another important regulator of p53 is the tumor suppressor p19 ARF , the product of the alternative reading frame from the CDKN2A locus. p19 ARF is deleted in some human tumors, and mice lacking it show a high incidence of spontaneous tumors (Sherr, 1998; Chin et al., 1998) . p19 ARF cooperates with p53 by neutralizing the inhibitory eect of Mdm2 on p53, resulting in the stabilization of active p53 (Sherr, 1998) . p19 ARF interacts directly with both p53 and Mdm2 , prevents the nuclear-cytoplasmic shuttling of Mdm2 (Tao and and sequesters Mdm2 into the nucleolus (Weber et al., 1999; Tao and Levine, 1999) . Further, p19
ARF inhibits the ability of Mdm2 to promote the ubiquitination of p53 (Honda and Yasuda, 1999) . Although p19 ARF does not mediate DNA damage response to p53 , it is activated by c-Myc , E2F-1 , and E1A (de Stanchina et al., 1998), thereby integrating oncogenic and proliferative signals to p53. c-Myc activates p53-dependent apoptosis, at least in part, via the induction of p19 ARF . Mouse embryo ®broblasts (MEFs) lacking ARF or p53 are resistant to c-Myc-mediated apoptosis . By inhibiting Rb, E1A releases E2F-1 such that it can induce the p19 ARF gene (de Stanchina et al., 1998) . On the other hand, the p19 ARF promoter is downregulated by p53 (Robertson and Jones, 1998) . Thus, a regulatory feedback loop exists between p53, Rb/E2F-1 and p19
ARF Robertson and Jones, 1998) , which may account for the elevated p19 ARF expression in p53-de®cient cells (Sherr, 1998) . In addition, Rb can directly regulate the stability and apoptotic function of p53 by blocking Mdm2-dependent degradation of p53 (Hsieh et al., 1999) . pRb binds Mdm2 and forms a trimeric complex with p53, thereby stabilizing p53 and relieving the inhibitory eect of Mdm2 on p53-mediated apoptosis (Hsieh et al., 1999) . Overall, the modulation of Mdm2 function appears to be a common mechanism for regulating p53.
Other cellular proteins involved in the accumulation of p53 Recent studies revealed several proteins that can stabilize the p53 protein, but the underlying mechanisms are unknown. The transcriptional co-activator p300 was shown to be essential for IR-induced accumulation and activation of p53, but has no eect on the basal level of p53 in untreated cells . p300 interacts with p53 and Mdm2 (Grossman et al., 1998; Yuan et al., 1999) , but the signi®cance of these interactions in the regulation of p53 degradation is still unclear. The poly(ADP-ribose)polymerase (PARP) interacts with p53 and plays a role in the stabilization and activation of p53 in response to DNA damage (Kumari et al., 1998; Wang et al., 1998) . In cells lacking PARP, wt p53 has a shorter half-life and it does not accumulate in response to etoposide treatment (Whitacre et al., 1995) . In addition, the Wilms tumor suppressor gene WT1 (Maheswaran et al., 1995) and the hypoxia-inducible factor 1a (HIF1a) cause stabilization of p53. Whether Mdm2 or JNK1 are involved in the stabilization eect of p53 by these proteins, is yet to be demonstrated.
Regulation of p53 activity
Besides the regulation of p53 stability, its activities may be modulated. The p53 protein can be converted from a latent form to an active form by a variety of mechanisms including interaction with damaged DNA, post-translational modi®cations, and protein-protein interaction. The C-terminus of p53 binds directly to sites of damaged DNA including double strand DNA break, mismatches and single-stranded DNA (reviewed in Janus et al., 1999) . A single double strand break in DNA is sucient to activate p53 (Huang et al., 1996) . Further, DNA binding by p53 could be stimulated by a protein fragment spanning the entire C-terminus (311 ± 393) (Jayaraman and Prives, 1995) , or smaller peptides spanning a region within the C-terminal 30 amino acids (364 ± 393) (Hupp et al., 1995) . The occupation of the C-terminus of p53 is believed to relieve it from negative regulation and thereby expose the DNA binding core of p53 (Hupp et al., 1995; Jayaraman and Prives, 1999) . Another negative regulatory region in p53 was identi®ed to be the proline-rich domain. Synthetic peptides spanning this domain (80 ± 93) were able to activate p53 for sequence-speci®c DNA binding in vitro (MuÈ llerTiemann et al., 1998).
Phosphorylation of p53 at the N-terminus on serines 15 (ATM and DNA-PK), 20, 33 (JNK1) and 37 (DNA-PK) increases p53 sequence-speci®c DNA binding, and consequently enhance the SST of its target genes (Banin et al., 1998; Canman et al., 1998; Hu et al., 1997; Khanna et al., 1998; Sakaguchi et al., 1998; Shieh et al., 1997 Shieh et al., , 1999 Tibbetts et al., 1999) . Cells lacking functional ATM (A-T cells) or DNA-PK are defective in DNA binding and p53 response to IR, indicating that both proteins have to be present for the full p53 response (Barlow et al., 1997; Woo et al., 1998) . p53 activity is also modulated by phosphorylations at the C-terminus. Serine 392 is phosphorylated by casein kinase II, serine 315 by CDKs, and serines 371, 376 and 378 by protein kinase C (Jayaraman and Prives, 1999; Meek, 1998) . The phosphorylation of each one of these serine sites is enough to increase the sequence-speci®c DNA-binding of p53 (Meek, 1998) . Possibly these phosphorylations relieve p53-SST from negative regulation. Among the C-terminal serine residues, only serine 392 is phosphorylated following UV radiation, but not after IR (Kapoor and Lozano, 1998; Lu et al., 1998) , and this stabilizes the tetramer formation of p53 (Sakaguchi et al., 1997) . This phosphorylation was shown to be mediated by the p38 MAP kinase .
Phosphorylation of p53 at the N-terminus enhances its binding to the transcriptional co-activator p300 (Lambert et al., 1998) , which acetylates p53 on Lys 382 . p53 is also acetylated on Lys 320 within its nuclear localization sequence by PCAF, another histone transacetylase . These acetylations increase the sequence-speci®c DNAbinding of p53 (Lambert et al., 1998; Sakaguchi et al., 1998) .
Besides phosphorylation and acetylation, IR also leads to speci®c dephosphorylation of p53. Serine 376 is phosphorylated in unstimulated cells, but undergo dephosphorylation in response to IR in an ATMdependent manner. This modi®cation creates a consensus binding sites for 14-3-3 proteins (Waterman et al., 1998) . The association of 14-3-3 with p53 increases the anity of p53 for sequence-speci®c DNA (Waterman et al., 1998) . Interestingly, the 14-3-3s gene is induced by p53 (Hermeking et al., 1997) , thereby forming a potential positive feedback loop for p53 activation.
As discussed previously, the interaction of p53 with several proteins enhances its stabilization. In the cases of HIF-a, c-Abl, p300, PARP, WT-1, p19 ARF and pRb, the accumulation of p53 was associated with an increase in SST. In some cases these interactions may also in¯uence the cellular response to p53 activation. It is dicult to quantitate the extent by which the accumulation of p53 contributes to its SST activity. Other proteins bind p53 and enhance its SST without aecting its stability. These include 14-3-3 (Waterman et al., 1998) , BRCA1 , and the p33 ING1 tumor-suppressor candidate (Garkavtsev et al., 1998) . p33 ING1 leads to p53-mediated growth arrest and to increased sensitivity to DNA damage and ectopic expression of p53. Inhibition of p33 ING1 expression by antisense cDNA impairs growth-inhibition by p53. The dependency of p53 on multiple factors for its proper activity raises the question whether p53 is fully functional in the 50% of human tumors that retain a wt p53 gene (Oren, 1998) .
The transactivation activity of p53 may be depressed by other factors, including the mortalin gene mot-2, a hsp70 family member p53 which abrogates nuclear translocation of p53 (Wadhwa et al., 1998) , BRCA2 (Marmorstein et al., 1998) and the anti-apoptotic protein Bcl-2 (Froesch et al., 1999) . c-Jun may also negatively regulate p53 by repressing transcription of p53 by direct binding to a variant AP-1 site in the p53 promoter (Schreiber et al., 1999) .
The choice between growth arrest and apoptosis
The ability of p53 to promote growth arrest and apoptosis raises the intriguing question of what determines the choice between these two cellular responses. This question has been addressed extensively by numerous studies that revealed several determinants that can in¯uence this choice. These include the cell type, the oncogenic composition of the cell, the extracellular stimuli and the intensity of the stress conditions, the level of p53 expression and its interaction with speci®c proteins. These factors aect the activity of p53 and how the cell responds to it. The following sections outline some of these factors which in¯uence the cellular response to p53.
The cellular context
The cell type The cell type may aect the outcome of DNA-damage induced p53-response. T lymphocytes usually respond to DNA damage by undergoing extensive apoptosis, while ®broblasts enter a cell-cycle arrest (Bates and Vousden, 1999) . The dierence in the apoptotic threshold of the two cell types may be a re¯ection of their dierent`life style'. The T lymphocytes have to respond rapidly to antigen stimulus, undergo clonal expansion, and subsequently die in order to limit the immunological response. This cell death is highly dependent on the Fas-Fas ligand death-signaling pathway. Another reason for this dierence in susceptibility to apoptosis lies in their dierential ability to induce bax in response to IR. Lymphoid myeloid cell lines exposed to IR induce bax and undergo rapid apoptosis, whereas ®broblastoid cell lines do not (reviewed in Amundson et al., 1998) . Thus, multiple mechanisms make the T lymphocyte more prone to apoptosis. Moreover, the increased susceptibility of bone marrow derived cells to alkylating agents may stem from the low expression level of the DNA repair protein O 6 -methylguanine DNA methyltransferase (Maze et al., 1996) .
The eciency of DNA repair mechanisms The ability of the cells to repair the defective DNA may be critical for the outcome of the p53-response. As long as DNA repair is not completed, p53 may remain active. If the repair process is rapidly completed, the period of p53 activation is consequently short, whereas the opposite is the case for extensive DNA damage. There is evidence that cells impaired in one of the DNA repair mechanisms exhibit higher radiosensitivity and chemosensitivity. Typical examples are cells with defective NER activity, such as those from Xeroderma pigmentosum, Trichothiodystrophy, or Cockayne Syndrome patients. Cells derived from these patients show increased sensitivity to UV radiation (Dumaz et al., 1997) , faster accumulation of p53, and the protein remains stable for longer time than in normal cells. Lower dose of UV is sucient to trigger p53 accumulation in the NER-de®cient cells (Dumaz et al., 1997) . These eects promote apoptotic death rather than growth arrest. Similarly, McKay et al. (1998) observed that ®broblasts de®cient in transcription coupled repair showed enhanced induction of apoptosis, and increased expression of p53, p21 and bax expression than the normal counterparts in response to low UV dose.
Oncogenic composition of the cell The Rb-E2F1 balance. Generally, the activation of p53 in normal cells results in cell-cycle arrest or senescence, whereas in transformed cells p53 usually promotes apoptosis (Figure 3 ) (reviewed in Bates and Vousden, 1999) . The p53-pRb signaling pathway is abrogated by a variety of mechanisms in the majority of cancers (Levine, 1997) . This results in the deregulation of E2F-1 with the consequent induction of apoptosis (discussed previously). For instance, inactivation of pRb by the adenoviral E1A or the HPV E7 proteins triggers apoptosis (Jones and Munger, 1997) , whereas reintroduction of pRb into HeLa cells (HPV infected) lowers their apoptotic sensitivity to p53 (Haupt et al., 1995a) . This is consistent with the relative resistance of ®broblasts lacking E2F1 to DNA damage (Meng et al., 1999) , and impairment of apoptosis upon inhibition of CDK2 kinase, and acceleration of apoptosis when CDK2 is overexpressed (Gil Gomez et al., 1998) .
Activation of the p53-pRb growth arrest pathway may confer protection from p53-dependent death. Introduction of p21 switches the p53 response from apoptosis to growth arrest (Bissonnette and Hunting, 1998; Waldman et al., 1997) , consistent with the antiapoptotic function of p21 (Asada et al., 1999) . Further, the cytoplasmic p21 inhibits the activation of the apoptosis-regulating kinase 1 (ASK1) and JNK1/ SAPK (Asada et al., 1999) . Indeed, ®broblasts de®cient in p21 are impaired in IR-induced growth arrest (Brugarolas et al., 1995; Deng et al., 1995) , and p21-de®cient normal ®broblasts and tumor cells are more sensitive to p53-induced apoptosis (Gorospe et al., 1997; Polyak et al., 1996) . Similar susceptibility was seen upon cleavage of p21 by caspase, an early event during DNA damage-induced apoptosis (Gervais et al., 1998) . Taken together, the status of the Rb/E2F-1 checkpoint is crucial for the protection of cells from apoptosis.
The Bax/BCL-2 ratio Deregulation of pro-or antiapoptotic proteins can in¯uence the sensitivity of cell response to apoptotic stimuli. Speci®cally, the ratio between the expression of the anti-apoptotic Bcl-2 and the proapoptotic Bax can determine the cellular response to p53 (Figure 3) . The Bcl-2 family of proteins function at the point of convergence of multiple apoptotic signals (Dragovich et al., 1998) . Bcl-2 prevents the formation of reactive oxygen intermediates (ROI) (Hockenbery et al., 1993) and the release of AIF and cytochrome C from the mitochondria (Dragovich et al., 1998; Susin et al., 1999) . Mitochondrial membrane disruption appears to be a`point of no return' in the commitment to cell death. Prevention of this step is crucial for avoiding the apoptotic process. Bcl-2 blocks p53-dependent apoptosis in E1A transformed cells (Chiou et al., 1994) . This may, at least in part, be due to preventing nuclear import of p53 (Beham et al., 1997) .
Growth and survival factors Mitogenic growth stimulatory signals, such as cytokines, growth and survival factors, usually protect cells from apoptotic response to DNA damage by promoting growth arrest (Lin and Benchimol, 1995) . For example, IL-6 blocks p53-induced apoptosis of myeloid leukemia cells (Yonish- Figure 3 A model for the cellular decision to enter growth arrest or apoptosis in response to activated p53. The response to p53 is dierent in normal cells than in cancer cells, shown by the nonoverlapping circles. This dierence is largely in¯uenced by the synergistic eect of deregulated E2F-1 on p53-mediated apoptosis. The dierence is manifested at low levels of p53, where normal cells tend to growth arrest while cancer cells undergo apoptosis. The response of normal and cancer cells to high levels of p53 is quite similar (shown by the overlapping region) with a tendency for apoptosis. However, the presence of various cellular proteins (e.g., p21, p300, Rb, WT-1, Bcl-2) or extracellular survival factors may block apoptosis and switch the cellular response to growth arrest. The induction of high and low levels of p53 target genes is shown by large and small letters, respectively. ?indicates induction, whereas \ inhibition Rouach et al., 1991) , erythropoietin protects DP16 Friend erythroleukemia cells (Johnson et al., 1993) and IL-3 inhibits apoptosis of DA-1 cells (Gottlieb et al., 1996) . The cooperation of IL-3 and p53 in determining the cellular fate appears to be mediated through cleavage of the Rb protein by caspase activation following IL-3 withdrawal (Gottlieb and Oren, 1998) . The anti-apoptotic eect of these survival factors may be explained by the cross talk between growth signaling pathways and cell death signaling involving the Bcl-2 family members, such as Bad (Dragovich et al., 1998) . For example, upon growth factor receptor engagement (e.g., IL-3R), the serine/threonine Akt kinase phosphorylates Bad. Phosphorylated Bad is sequestered by the cytosolic protein 14-3-3, thus increasing the levels of free Bcl-2 and Bcl-X L (Zha et al., 1996) .
The intensity of the stress signal
The ®nding that extensive DNA damage induces apoptosis while mild damage tends to trigger growth arrest, raised the possibility that p53 expression levels may correlate with the intensity of the stress signals. This conjecture is now supported by the demonstration that UV doses can aect the repertoire and kinetics by which p53 target genes are induced. In ®broblasts exposed to low UV-B (300 nm) doses (50 J/m 2 ), p53 induces p21, but not bax, consistent with an increase in nucleotide excision repair (NER) activity (Li and Ho, 1998) . The opposite is true at higher doses of UV-B (over 200 J/m 2 ) where bax, but not p21, is induced by p53 with a subsequent induction of apoptosis (Li and Ho, 1998) . Similarly, the dose of UV-C (254 nm) can aect the kinetics by which p53-target genes are induced (Reinke and Lozano, 1997a) . Induction of p21 by p53 occurs within 6 h after exposure of ®broblasts to a low dose of UV-C (10 J/m 2 ), but there is no induction after exposure to a higher dose (50 J/ m 2 ). Under the same conditions (UV-C 10 J/m 2 ), there was a delay in Cyclin G and mdm2 induction (12 ± 24 h) followed by an increase in bax expression (after 24 h). An earlier induction of bax (after 6 h) occurs in response to 50 J/m 2 , with a concurrent induction of apoptosis (Reinke and Lozano, 1997a) . These studies indicate that cellular stress response to UV radiation depends on the UV dose, low doses promote growth arrest and DNA repair, while high doses results in apoptosis. It should be noted that by contrast to UV, at high doses of g-irradiation (2000 cGy), p21 expression is not suppressed, but rather increased (Bissonnette et al., 1997) .
The level of p53 expression
As a function of p53 expression level, it can either protect cells from death or promote apoptosis. This conjecture gained support when it was observed that low levels of p53 expression have anti-apoptotic activity (Lassus et al., 1996) , while high levels promote apoptosis (Chen et al., 1996) . The dosage dependency for inducing apoptosis is further demonstrated by the fact that bone marrow cells harboring a single p53 allele show an intermediate resistance to IR-induced apoptosis compared with their wild-type and p53-de®cient counterparts (Lotem and Sachs, 1993) . As Mdm2 is the major regulator of p53 expression, factors aecting Mdm2 expression and activity may have a major impact on the ®nal outcome of the p53 response. Uncontrolled high levels of p53 in embryos lacking Mdm2 expression are detrimental to the developing embryo (Jones et al., 1995) .
Dierential p53 promoter speci®city
Comparative studies revealed a tight correlation between the induction of distinct sets of p53 target genes and the ability of cells to arrest in G1 or to undergo apoptosis (Flaman et al., 1998; Friedlander et al., 1996; Ludwig et al., 1996) . These studies made use of p53 mutants (e.g., 120Arg, 175Pro, 175Cys, 175Leu, 175Ser, 181Leu, 181His, 254Phe, 283His) which acquired promoter speci®city. Speci®cally, these mutants remained active towards p21, but lost the ability to induce bax expression. The p53175Pro and p53181Leu mutants have also lost the ability to induce IGF-BP3 promoter (Ludwig et al., 1996) . Thus, only the high-anity (cell-cycle arrest) promoters remain sensitive to activation. The loss of binding to the consensus of the bax promoter can be`corrected' in some mutants (175Cys, 175Leu, 175Ser and 181Leu) if multiple binding sites are created (Flaman et al., 1998) , suggesting that the mutations cause reduced anity to speci®c sites. Dierences in anity to p21 and bax promoters may be explained by dierences in their consensus sequence. First, the p21 site contains two mismatches whereas the bax site contains three mismatches (Flaman et al., 1998) . The third mismatch in the bax sequence aects a major groove base contact with 120Lys, which may signi®cantly reduce the binding (Flaman et al., 1998) . Second, the p21 site contains AT in the center of each decamer versus AA in the bax site. Third, in the bax site the two decamers are not immediately adjacent (Thukral et al., 1995) . Hence, p53 has dierent anities for its target gene promoters. It would be valuable to extend the screen of the above p53 mutants to include the newly characterized target genes, such as PIG3 and 14-3-3s, that can in¯uence the choice between arrest and death.
Eect of p53 regulatory proteins
The ®ndings that mutations within p53 can alter its promoter speci®city raises the intriguing question as to whether physiological alterations in p53 can also aect its promoter speci®city. Several studies support this notion by showing that the speci®city of p53 SST may be in¯uenced by the pattern of post-translational modi®cations and by interaction with regulatory proteins. In thymocytes from ATM-de®cient mice, p21 induction is attenuated, while bax induction and p53-mediated apoptosis occur normally (Barlow et al., 1997) . This probably contributes to the high radiosensitivity of A-T cells. Thus, ATM may aect the cellular responses by altering the SST speci®city of p53. Also, the phosphorylation of p53 at serine 315 by CDKs can alter the speci®c DNA binding anity of p53 (Wang and Prives, 1995) .
Similarly, the binding of several other proteins to p53 can aect the cellular response to p53. The binding of p300 to p53 is essential for the induction of p21 and mdm2, and for protecting cells from p53-dependent apoptosis, presumably by promoting G1 growth arrest Yuan et al., 1999) . These activities of p53 can be blocked by expression of a dominant negative form of p300 (Avantaggiata et al., 1997) . Thus, p300 can in¯uence the cellular response to p53 . The thyroid hormone receptor b1 binds p53 and inhibits bax and GADD45, without aecting p21 induction (Barrera-Hernandez et al., 1998) . Another regulator of p53 is the WT1 tumor suppressor protein that is expressed in cells of the developing kidney and is inactivated in Wilm's tumor, a pediatric kidney cancer. The two proteins in¯uence each other's transcriptional activity (Englert, 1998) . WT1 enhances p53-mediated transcriptional activation and reduces its repression function (Englert, 1998) . WT1 interacts with p53 and antagonizes p53-mediated apoptosis (Maheswaran et al., 1995) .
It would be interesting to evaluate whether proteins that promote p53-mediated growth arrest (WT-1) preferentially enhance the anity of p53 to growth arrest inducing genes (e.g., p21), while proteins that promote p53-dependent apoptosis (e.g., HIF-a) switch the promoter preferences towards apoptosis inducing genes (e.g., bax).
Concluding remarks
The p53 protein integrates many extra-and intracellular stress signals into growth inhibitory responses. By doing so, p53 engages multiple signaling pathways, and as such it interacts with many proteins to form multimolecular complexes. Being a pivotal player in signaling pathways, p53 appears to be associated with many biological functions. Among these, the induction of growth arrest/senescence and apoptosis are crucial for its role as a tumor suppressor. Whether a given cell will suicide or live in response to activation of p53 is determined by many factors. Identi®cation of these factors, together with the fact that tumor cells are more sensitive to killing by p53, provides a basis for designing therapies for selective killing of cancer cells. In parallel to these developments, the picture in the jigsaw puzzle of p53 regulation is beginning to emerge, where Mdm2 forms the central piece. Here too, manipulating the extent by which Mdm2 blocks signaling by p53 may provide hope for future therapies.
